Gardasil Safety Questions Persist Despite Assurances From FDA/CDC
This article was originally published in The Pink Sheet Daily
Executive Summary
Adverse event data on cases of Guillane-Barre Syndrome fuel questions about the safety of the vaccine.
You may also be interested in...
Cervarix, Gardasil Set For FDA Advisory Committee Review
GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.
Cervarix, Gardasil Set For FDA Advisory Committee Review
GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.
Merck Plans Gardasil Campaign Targeting “Mid-adult” Women
FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.